凯普生物2026年1月26日涨停分析：专利授权+实控人增持+业务拓展

Group 1 - The core viewpoint of the news is that Capbio (凯普生物) experienced a significant stock price increase, reaching a limit up of 20.03% on January 26, 2026, with a total market capitalization of 4.687 billion yuan [1] - Capbio has recently announced the acquisition of multiple domestic and international patent authorizations, enhancing its technological barriers and core competitiveness [2] - The actual controller, Ms. Wang Jianyu, has completed an increase in holdings amounting to 18.12 million yuan and plans to continue increasing her stake, signaling confidence in the company's development [2] - The company has expanded its business scope by obtaining production qualifications for Class III in vitro diagnostic reagents and Class II obstetric and gynecological instruments [2] - For the first three quarters of 2025, Capbio reported a narrowing of net losses attributable to shareholders by 51.25%, with operating cash flow increasing by 173.06% to 121 million yuan, indicating an improvement in operational conditions [2] - Capbio, as an integrated supplier of molecular diagnostic products and services, is expected to benefit from the growth in the in vitro diagnostics sector within the biopharmaceutical industry [2] - On the market performance side, the biopharmaceutical sector saw active movements, with Capbio's limit-up creating a certain sector linkage effect [2] - Technical indicators such as the MACD forming a golden cross and breaking through the upper Bollinger Band may attract more capital attention [2] - There was likely a flow of main funds into the stock, contributing to the price surge [2]